BluMaiden Biosciences is a platform company that has developed transformational Artificial Intelligence that identifies biomarkers and therapeutics from within the human microbiome. The Company engages in clinical trials and R&D collaborations with Clinical Institutions, Biotech, Pharma, and MNCs to discover novel drugs and targets that can lead to:

1. Therapeutics
2. Diagnostics
3. Patient Stratification

Run by an accomplished founding team and backed by a panel of experienced and global investors and scientific advisors, BluMaiden is building a sustainable business with enduring competitive advantage.

BluMaiden Biosciences provides an end-to-end solution for clinical trials by providing microbiome sample collection, handling, sequencing and apply our state-of-the-art genome-resolved metagenome analysis. We are working with some of the leading global players across multiple disease areas and generating analytical outputs that add greater value to clinical trials end-points.

BluMaiden Biosciences has built proprietary AI-driven platforms that access the chemical space in human microbiome for small molecule drug-target therapeutics discovery. With human clinical-evidence as a primary input, this natural product offers a wider and more biologically relevant chemical space than typical synthetic small molecule libraries. The Company engages in with Pharma to develop the small molecule assets or platform technology.

BluMaiden Biosciences has built and launched digital health platforms to translate our microbiome-based health and wellness insights for the benefit of consumers. This platform is available globally to businesses by out-license and integration with existing customer base across a broad range of consumer segments.